Search bioRxiv⌕ Search

Biology subjects

Sanz Garcia, E.

Publications and source records attributed to Sanz Garcia, E..

2 recordsLinked to original sources

Consensus molecular subtypes define distinct evolutionary trajectories of biliary tract cancers

Introduction Biliary tract cancer (BTC) comprises a family of rare malignancies subclassified by anatomy and pathology. However, this scheme may obscure shared biology and limit patient stratification. Objectives We tested whether BTC heterogeneity can be explained by coherent latent axes and evaluated the potential to unify diverse clinical and genomic factors under a tractable biological framework Methods We performed whole-genome and transcriptome sequencing of 180 tumors enriched for tumor cells by laser capture microdissection to identify shared programs in BTC. Results Network integration across transcriptomic classes identified two consensus cancer subtypes (CCS). CCS segregated with anatomical location of primary tumor and gene expression marker analyses suggest subtypes reflect tumor cell of origin differences. CCS displayed strikingly divergent molecular landscapes, explaining more variance than anatomical location of primary tumor. CCS-B tumors were mutationally loaded with clock-like and APOBEC signatures and extrachromosomal DNA, whereas CCS-A tumors were characterized by chromosome-arm deletions. Conclusion Our approach showed that harnessing the genomic and transcriptomic diversity of BTC uncovers novel biology and improves stratification.

cancer biology↗

Hematopoietic Tet2 inactivation enhances the response to checkpoint blockade immunotherapy

Somatic mutations inactivating TET2 are among the most common drivers of clonal hematopoiesis (CH). While TET2 inactivation is associated with monocyte-derived inflammation and improved chimeric antigen-receptor-T cell function, its impact on immunotherapy response is unknown. In our mouse model, hematopoietic Tet2 mutation enhanced immune checkpoint blockade (ICB) response. Enhanced ICB response with Tet2 mutation required phagocytes, CD4 and CD8 T cells. Mechanistically, in Tet2-mutant tumor-infiltrating leukocytes (TILs), ICB preferentially induced anti-tumor states and restricted cell states linked to tumor progression. Tet2-mutant monocytes activated costimulatory programs, while Tet2-mutant T cells showed enhanced T cell memory signatures, lesser exhaustion and decreased regulatory phenotype. Our murine data was clinically relevant, since we found that melanomas from patients with TET2 driver mutation-CH (TET2-CH) showed enhanced immune infiltration, T cell activation, and T cell memory programs. In melanoma patients treated with ICB, TET2-CH was associated with 6-fold greater odds of clinical benefit. Collectively, our data establishes that hematopoietic Tet2 inactivation primes leukocytes for anti-tumor states associated with immunotherapy response and provides a potential biomarker for personalized therapy.

cancer biology↗